Dr Reddy’s Laboratories has dipped nearly 3% to Rs 2,538, extending its previous day’s 4% fall, after the pharma major reported a 16% year on year (yoy) decline in consolidated net profit at Rs 482 crore for the quarter ended March 31, 2014 (Q4), due to lower sales growth, higher SG&A (selling, general and administrative) expenses. The company had registered a profit of Rs 571 crore in the same quarter year ago.
Net sales of the company in Q4, 2013-14 rose to Rs 3,481 crore from Rs 3,340 crore in the year-ago period.
The company said the SG&A expenses rose 18% yoy to Rs 1,031 crore for the fourth quarter of last fiscal, from Rs 872 crore in the year-ago period.
However, analyst at Angel Broking maintains buy recommendation on the stock with a price target of Rs 3,634.
The stock opened at Rs 2,600 and touched a low of Rs 2,525 on the NSE. A combined 595,000 shares changed hands on the counter so far on the NSE and BSE.
Net sales of the company in Q4, 2013-14 rose to Rs 3,481 crore from Rs 3,340 crore in the year-ago period.
The company said the SG&A expenses rose 18% yoy to Rs 1,031 crore for the fourth quarter of last fiscal, from Rs 872 crore in the year-ago period.
However, analyst at Angel Broking maintains buy recommendation on the stock with a price target of Rs 3,634.
The stock opened at Rs 2,600 and touched a low of Rs 2,525 on the NSE. A combined 595,000 shares changed hands on the counter so far on the NSE and BSE.
